Overview
Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is a synthetic dipeptide nootropic developed in Russia and reported to be 1,000 times more potent than piracetam by weight. It is a prodrug for cycloprolylglycine, an endogenous neuropeptide that modulates AMPA receptors. Noopept upregulates NGF and BDNF expression, enhances alpha and beta brain wave activity, and provides neuroprotection against glutamate excitotoxicity and oxidative stress.
Mechanism of action
Noopept is hydrolyzed to cycloprolylglycine, which potentiates AMPA receptor conductance and enhances long-term potentiation in hippocampal circuits. It increases NGF and BDNF mRNA expression in the hippocampus and cortex, supporting neuronal maintenance and synaptic plasticity. It also inhibits acetylcholinesterase mildly, raises acetylcholine availability, and reduces lipid peroxidation.
Selected literature
- [01]
Noopept stimulates NGF and BDNF expression in rat hippocampus
Ostrovskaya R.U. et al. · Bulletin of Experimental Biology and Medicine · 2008
Noopept significantly increased NGF and BDNF mRNA levels in rat hippocampus and cortex after 28 days of administration.
- [02]
Noopept and cognitive function in patients with mild cognitive impairment
Neznamov G.G. & Teleshova E.S. · Neuroscience and Behavioral Physiology · 2009
Noopept improved memory, attention, and cognitive performance in a randomized controlled trial of patients with mild cognitive impairment.
- [03]
Neuroprotective effects of Noopept against glutamate excitotoxicity
Gudasheva T.A. et al. · European Journal of Pharmacology · 1996
Noopept protected cortical neurons against glutamate-induced excitotoxicity and reduced lipid peroxidation markers in neuronal cultures.
The information on this page is summarized from the published research literature and is provided for reference and educational purposes only. It is not medical advice and should not be used to guide treatment decisions. Our peptides are sold for in-vitro research and laboratory use only.